Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001628280-25-008433
Filing Date
2025-02-27
Accepted
2025-02-27 07:15:57
Documents
173
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K cccc-20241231.htm   iXBRL 10-K 2022846
2 EX-10.19 c4t-mkdgcollaborationagr.htm EX-10.19 205342
3 EX-19.0 statementofcompanypolicy.htm EX-19.0 26394
4 EX-21.1 exhibit2112024.htm EX-21.1 2456
5 EX-23.1 exhibit2312024.htm EX-23.1 1959
6 EX-31.1 cccc-20241231x10kex311.htm EX-31.1 10799
7 EX-31.2 cccc-20241231x10kex312.htm EX-31.2 10725
8 EX-32.1 cccc-20241231x10kex321.htm EX-32.1 5070
9 EX-32.2 cccc-20241231x10kex322.htm EX-32.2 5094
15 c4t-mkdgcollaborationagr001.jpg GRAPHIC 56960
16 c4t-mkdgcollaborationagr002.jpg GRAPHIC 181971
17 c4t-mkdgcollaborationagr003.jpg GRAPHIC 194320
18 c4t-mkdgcollaborationagr004.jpg GRAPHIC 140704
19 c4t-mkdgcollaborationagr005.jpg GRAPHIC 25039
20 c4t-mkdgcollaborationagr006.jpg GRAPHIC 229440
21 c4t-mkdgcollaborationagr007.jpg GRAPHIC 197948
22 c4t-mkdgcollaborationagr008.jpg GRAPHIC 235106
23 c4t-mkdgcollaborationagr009.jpg GRAPHIC 229235
24 c4t-mkdgcollaborationagr010.jpg GRAPHIC 223483
25 c4t-mkdgcollaborationagr011.jpg GRAPHIC 227469
26 c4t-mkdgcollaborationagr012.jpg GRAPHIC 219613
27 c4t-mkdgcollaborationagr013.jpg GRAPHIC 214202
28 c4t-mkdgcollaborationagr014.jpg GRAPHIC 250609
29 c4t-mkdgcollaborationagr015.jpg GRAPHIC 153866
30 c4t-mkdgcollaborationagr016.jpg GRAPHIC 145422
31 c4t-mkdgcollaborationagr017.jpg GRAPHIC 237033
32 c4t-mkdgcollaborationagr018.jpg GRAPHIC 224382
33 c4t-mkdgcollaborationagr019.jpg GRAPHIC 257210
34 c4t-mkdgcollaborationagr020.jpg GRAPHIC 304635
35 c4t-mkdgcollaborationagr021.jpg GRAPHIC 239826
36 c4t-mkdgcollaborationagr022.jpg GRAPHIC 258468
37 c4t-mkdgcollaborationagr023.jpg GRAPHIC 251033
38 c4t-mkdgcollaborationagr024.jpg GRAPHIC 279538
39 c4t-mkdgcollaborationagr025.jpg GRAPHIC 252898
40 c4t-mkdgcollaborationagr026.jpg GRAPHIC 161118
41 c4t-mkdgcollaborationagr027.jpg GRAPHIC 224499
42 c4t-mkdgcollaborationagr028.jpg GRAPHIC 213357
43 c4t-mkdgcollaborationagr029.jpg GRAPHIC 253589
44 c4t-mkdgcollaborationagr030.jpg GRAPHIC 272012
45 c4t-mkdgcollaborationagr031.jpg GRAPHIC 285196
46 c4t-mkdgcollaborationagr032.jpg GRAPHIC 283346
47 c4t-mkdgcollaborationagr033.jpg GRAPHIC 265829
48 c4t-mkdgcollaborationagr034.jpg GRAPHIC 290522
49 c4t-mkdgcollaborationagr035.jpg GRAPHIC 257099
50 c4t-mkdgcollaborationagr036.jpg GRAPHIC 252177
51 c4t-mkdgcollaborationagr037.jpg GRAPHIC 231391
52 c4t-mkdgcollaborationagr038.jpg GRAPHIC 297847
53 c4t-mkdgcollaborationagr039.jpg GRAPHIC 295689
54 c4t-mkdgcollaborationagr040.jpg GRAPHIC 224617
55 c4t-mkdgcollaborationagr041.jpg GRAPHIC 271848
56 c4t-mkdgcollaborationagr042.jpg GRAPHIC 280454
57 c4t-mkdgcollaborationagr043.jpg GRAPHIC 249669
58 c4t-mkdgcollaborationagr044.jpg GRAPHIC 293352
59 c4t-mkdgcollaborationagr045.jpg GRAPHIC 183253
60 c4t-mkdgcollaborationagr046.jpg GRAPHIC 209287
61 c4t-mkdgcollaborationagr047.jpg GRAPHIC 250114
62 c4t-mkdgcollaborationagr048.jpg GRAPHIC 160844
63 c4t-mkdgcollaborationagr049.jpg GRAPHIC 262368
64 c4t-mkdgcollaborationagr050.jpg GRAPHIC 292671
65 c4t-mkdgcollaborationagr051.jpg GRAPHIC 261166
66 c4t-mkdgcollaborationagr052.jpg GRAPHIC 286764
67 c4t-mkdgcollaborationagr053.jpg GRAPHIC 248330
68 c4t-mkdgcollaborationagr054.jpg GRAPHIC 301400
69 c4t-mkdgcollaborationagr055.jpg GRAPHIC 275696
70 c4t-mkdgcollaborationagr056.jpg GRAPHIC 144901
71 c4t-mkdgcollaborationagr057.jpg GRAPHIC 134674
72 c4t-mkdgcollaborationagr058.jpg GRAPHIC 60308
73 c4t-mkdgcollaborationagr059.jpg GRAPHIC 23870
74 cccc-20241231_g1.jpg GRAPHIC 57781
75 cccc-20241231_g2.jpg GRAPHIC 46888
76 cccc-20241231_g3.jpg GRAPHIC 69482
77 cccc-20241231_g4.jpg GRAPHIC 83757
78 cccc-20241231_g5.jpg GRAPHIC 37811
79 cccc-20241231_g6.jpg GRAPHIC 8409
80 cccc-20241231_g7.jpg GRAPHIC 2945
81 cccc-20241231_g8.jpg GRAPHIC 9503
82 statementofcompanypolicy001.jpg GRAPHIC 243109
83 statementofcompanypolicy002.jpg GRAPHIC 254386
84 statementofcompanypolicy003.jpg GRAPHIC 241709
85 statementofcompanypolicy004.jpg GRAPHIC 257097
86 statementofcompanypolicy005.jpg GRAPHIC 200612
87 statementofcompanypolicy006.jpg GRAPHIC 210979
88 statementofcompanypolicy007.jpg GRAPHIC 243034
89 statementofcompanypolicy008.jpg GRAPHIC 163436
  Complete submission text file 0001628280-25-008433.txt   31568329

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cccc-20241231.xsd EX-101.SCH 67165
11 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cccc-20241231_cal.xml EX-101.CAL 98601
12 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cccc-20241231_def.xml EX-101.DEF 317601
13 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cccc-20241231_lab.xml EX-101.LAB 830543
14 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cccc-20241231_pre.xml EX-101.PRE 563301
176 EXTRACTED XBRL INSTANCE DOCUMENT cccc-20241231_htm.xml XML 1290225
Mailing Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472 (617) 231-0700
C4 Therapeutics, Inc. (Filer) CIK: 0001662579 (see all company filings)

EIN.: 475617627 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39567 | Film No.: 25672983
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)